Deutsche Märkte geschlossen
  • DAX

    14.370,72
    +106,16 (+0,74%)
     
  • Euro Stoxx 50

    3.942,62
    +21,35 (+0,54%)
     
  • Dow Jones 30

    33.476,46
    -305,02 (-0,90%)
     
  • Gold

    1.809,40
    +7,90 (+0,44%)
     
  • EUR/USD

    1,0545
    -0,0014 (-0,14%)
     
  • BTC-EUR

    16.271,06
    -199,43 (-1,21%)
     
  • CMC Crypto 200

    402,11
    -4,14 (-1,02%)
     
  • Öl (Brent)

    71,59
    +0,13 (+0,18%)
     
  • MDAX

    25.604,18
    +139,53 (+0,55%)
     
  • TecDAX

    3.043,52
    +0,03 (+0,00%)
     
  • SDAX

    12.326,40
    +35,02 (+0,28%)
     
  • Nikkei 225

    27.901,01
    +326,58 (+1,18%)
     
  • FTSE 100

    7.476,63
    +4,46 (+0,06%)
     
  • CAC 40

    6.677,64
    +30,33 (+0,46%)
     
  • Nasdaq Compositive

    11.004,62
    -77,39 (-0,70%)
     

IRLAB to present at Redeye Life Science Day 2022

IRLAB Therapeutics

GOTHENBURG, SE / ACCESSWIRE / November 24, 2022 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, November 24, 2022 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson's disease, today announced that the company will present and participate at Redeye Life Science Day 2022 on Thursday, November 24, 2022.

Richard Godfrey, CEO, will participate in an interview segment at 11:40 CET on Thursday, November 24, 2022. A pre-recorded company presentation is available via the event platform. Follow the live broadcast at https://www.redeye.se/events/850947/redeye-life-science-day.

A recording of the interview and presentation will be made available on our company website, www.irlab.se, following the event.

For more information:

Richard Godfrey, CEO
Phone: +46 730 70 69 00
E-mail: richard.godfrey@irlab.se

About IRLAB

IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.

IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.

Attachments

IRLAB to present at Redeye Life Science Day 2022

SOURCE: IRLAB Therapeutics



View source version on accesswire.com:
https://www.accesswire.com/728199/IRLAB-to-present-at-Redeye-Life-Science-Day-2022